Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-tacrine(10)-hupyridone is a synthetic small molecule designed as a dual-binding acetylcholinesterase inhibitor. It incorporates a tacrine moiety linked via a decyl chain to a hupyridone fragment. Tacrine is known as a reversible cholinesterase inhibitor; the addition of the hupyridone group enhances binding affinity and selectivity for acetylcholinesterase. This compound was developed to improve potency and reduce side effects compared to tacrine alone. Preclinical studies have shown that it inhibits acetylcholinesterase in a mixed competitive manner with high potency and can reverse cognitive impairments in animal models of Alzheimer's disease by crossing the blood-brain barrier and reducing brain AChE activity[6][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (S)-tacrine(10)-hupyridone.